title: Acromegaly: Beyond surgery.
abstract: Acromegaly is characterized by chronic, excess secretion of growth hormone (GH) from a pituitary adenoma, and elevated hepatic insulin-like growth factor 1 (IGF-1) levels. Significant progress has been made in the development of medical therapies to achieve biochemical and symptomatic control in acromegaly. In this review we discuss the three currently available medical therapies, which include somatostatin analogs, dopamine agonists and pegvisomant. We describe a step-wise approach in which a somatostatin analog is followed by the addition of a dopamine agonist, and then if required the addition of or replacement by pegvisomant. New somatostatin agonists such as pasireotide, and the introduction of new orally-acting somatostatin agonists, should increase the therapeutic choices available in the near future.
authors: Oxford Centre for Diabetes, Endocrinology and Metabolism, Churchill Hospital, University of Oxford, United Kingdom.
authors: Gaya
authors: G
authors: Thanabalasingham
authors: Ashley B
authors: AB
authors: Grossman
keywords: Acromegaly; cabergoline; lanreotide; medical therapy; octreotide; pasireotide; pegvisomant; somatostatin analogs
references: J Clin Endocrinol Metab. 1998 Sep;83(9):3034-40
references: 9745397
references: Pituitary. 2011 Jun;14(2):125-33
references: 21063787
references: Eur J Endocrinol. 2009 Aug;161(2):331-8
references: 19465485
references: J Clin Endocrinol Metab. 2012 Apr;97(4):1187-93
references: 22278424
references: Eur J Endocrinol. 2005 Mar;152(3):379-87
references: 15757854
references: Lancet. 2005 May 7-13;365(9471):1644-6
references: 15885297
references: J Clin Endocrinol Metab. 2009 May;94(5):1509-17
references: 19208732
references: J Clin Endocrinol Metab. 2011 May;96(5):1327-35
references: 21325455
references: Clin Endocrinol (Oxf). 2007 Jun;66(6):859-68
references: 17465997
references: J Clin Endocrinol Metab. 2005 Aug;90(8):4465-73
references: 15886238
references: J Clin Endocrinol Metab. 2005 Jul;90(7):4081-6
references: 15886256
references: Eur J Endocrinol. 2012 Jan;166(1):21-6
references: 21993154
references: J Clin Endocrinol Metab. 2010 Jun;95(6):2781-9
references: 20410233
references: J Clin Endocrinol Metab. 2012 May;97(5):1589-97
references: 22362824
references: Eur J Endocrinol. 2009 Jul;161(1):21-5
references: 19411301
references: J Clin Endocrinol Metab. 2006 Apr;91(4):1397-403
references: 16449332
references: J Clin Endocrinol Metab. 2002 Jul;87(7):3013-8
references: 12107192
references: Lancet. 2001 Nov 24;358(9295):1754-9
references: 11734231
references: J Clin Endocrinol Metab. 2004 Feb;89(2):667-74
references: 14764779
references: Clin Endocrinol (Oxf). 2009 May;70(5):757-68
references: 19178516
references: J Clin Endocrinol Metab. 2010 Jul;95(7):3141-8
references: 20410227
references: Clin Endocrinol (Oxf). 2009 Oct;71(4):549-57
references: 19438906
references: N Engl J Med. 2012 Mar 8;366(10):914-24
references: 22397653
references: J Clin Endocrinol Metab. 2008 Jan;93(1):61-7
references: 17971431